Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition

Tao Chen¹, Jing Wang¹, Chenhui Li¹, Weining Zhang², Luyong Zhang¹, Lufan An³, Tao Pang¹, Xinzhong Shi⁴ & Hong Liao¹

1Jiangsu Center for Drug Screening, China Pharmaceutical University, Nanjing 210009, P.R.China, 2School of Medical Science and Laboratory Medicine, Jiangsu University, Zhenjiang 212013, P.R.China, 3Jiangsu D&R Pharmaceutical Co. LTD, Taizhou 225300, P.R.China, 4School of Science, China Pharmaceutical University, Nanjing 210009, P.R.China.

Evidence suggests that thrombin, a blood coagulation serine protease, mediates neuronal injury in experimental cerebral ischemia. Here, we test the hypothesis that nafamostat mesilate, a serine protease inhibitor, may ameliorate ischemia-induced neuronal damage through thrombin inhibition after ischemic stroke. Focal ischemia was induced in adult Sprague-Dawley rats by occlusion of the middle cerebral artery for 2 hours followed by 22 hours of reperfusion. The administration of nafamostat mesilate during ischemia and reperfusion reduced the brain infarct volume, edema volume and neurological deficit. Thrombin expression and activity in the ipsilateral striatum were increased after ischemia, whereas the administration of nafamostat mesilate significantly inhibited thrombin expression and activity. Immunostaining showed that the majority of thrombin was expressed in neurons. TUNEL staining showed that nafamostat mesilate reduced the number of dying cells during ischemia. A rat behavioral test showed that nafamostat mesilate treatment significantly improved the learning ability of ischemic rats. These results suggest that nafamostat mesilate may have a potential therapeutic role for neuroprotection against focal cerebral ischemia through thrombin inhibition.

Stoke can elicit many damaging events, such as blood-brain barrier (BBB) disruption, brain edema, and especially the induction of deleterious factors, such as leakage of thrombin from peripheral blood to the brain, which can cause brain injury. Thrombin is a multifunctional serine protease generated by prothrombin cleavage, which can convert fibrinogen to fibrin during blood coagulation. However, mounting evidence indicates that thrombin is also involved in a variety of pathological processes of brain diseases, including brain trauma, severe epilepsy, neurodegenerative disease and stroke, and others. It has been reported that thrombin levels are increased in the ischemic core zone. Following ischemia, the BBB becomes more permeable to high-molecular-weight proteins, such as the thrombin precursor prothrombin. The brain itself may also be a source of prothrombin. This hypothesis is supported by the fact that prothrombin mRNA is upregulated after cerebral ischemia. In addition, Factor Xa mRNA has been identified in the brain, which is required for the cleavage of prothrombin to thrombin, suggesting that thrombin may be released even if the BBB is intact, leading to brain injury. Both in vivo and in vitro evidence have demonstrated that high levels of thrombin in the brain are deleterious. Therefore, thrombin can not only enter the brain during ischemia in which the blood–brain barrier is compromised, but can also be synthesized in the brain and eventually exerts damage to brain tissue and induces a cognitive function deficit.

Nafamostat mesilate (NM), a synthetic serine protease inhibitor, is widely used in patients with disseminated intravascular coagulopathy or pancreatitis. It is also reported that this agent suppressed ischemia-induced injury in the myocardium and subarachnoid hemorrhage-induced cerebral vasospasm. NM inhibits several serine proteases including thrombin, which is inhibited in a competitive manner with an inhibition constant (Kᵢ) value of $10^{-7}$–$10^{-6}$ M. As thrombin plays an important role in brain damage during ischemia, we evaluated the effect of nafamostat mesilate in a rat model of acute cerebral ischemia in the present study.
**Results**

The effects of NM on infarct volume, edema and neurologic deficit in rats after MCAO. The procedure for the tMCAO model and various drug treatments were performed according to the methods shown in Fig. 1A. The NM-treated and argatroban-treated groups showed decreased infarct volumes compared with the vehicle group (Fig. 1B and C). A significant increase in the brain water content was revealed in rats 24 hours after MCAO when compared with the sham group (Fig. 1D), while NM treatment (0.1 mg/kg or 1 mg/kg) significantly decreased the ischemia-induced water content increase (Fig. 1D). Moreover, NM treatment significantly ameliorated the total neurological deficit score at four doses examined (0.1, 0.3, 1 or 3 mg/kg) (Fig. 1E). These results show that NM can improve the infarct volume, brain edema and neurological deficit in rats after MCAO.

**The expression of thrombin increased in the ischemic regions of rats.** It has been shown that thrombin activation plays an important role during ischemia-induced brain injury. The topographic distribution of thrombin was investigated by double fluorescent staining in an ischemic/nonischemic cortical and striatum lesion at 24 hours after MCAO. Significant thrombin antigen was found in the regions of the ipsilateral hemisphere striatum; however, little thrombin antigen was detectable in the ipsilateral hemisphere cortex or contralateral striatum (Fig. 2A and B).

---

**Figure 1 | The effect of nafamostat mesilate (NM) on acute cerebral ischemia in rats at 24 h after MCAO.** (A) The drug administration schedule and experimental protocol are illustrated schematically. (B–D) NM dose-dependently ameliorated the ischemia-induced infarct volume (B, C), brain edema (D) and neurological deficits (E). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Vehicle (MCAO group); ###P < 0.001 vs. sham group, n = 8–10.
To determine whether the source of the increased thrombin expression in the ischemic brain regions was from the cerebral parenchyma or from vascular disruption, high-molecular-weight FITC-dextran was used to detect severe vascular disruption combined with a thrombin antibody for double staining. As shown in Fig. 2C–E, FITC-dextran staining alone and FITC-dextran double staining with a thrombin antibody were markedly increased in the ischemic striatum compared with the ischemic cortex, and there was a significant difference between the amount of staining in the ipsilateral and contralateral striatum. Double staining with the neuronal marker MAP-2 showed that the majority of thrombin was expressed in neurons (Fig. 2F). These results suggest that thrombin expression in the ischemic regions is either from vascular leakage or neurons.

**NM treatment decreased the expression and activity of thrombin in rats after MCAO.** A high expression level and activity of thrombin are associated with brain damage after ischemic stroke. Owing to NM’s activity as a serine protease inhibitor, we determined whether NM treatment could inhibit thrombin expression and activity in the striatum lesion at 24 hours after MCAO. The results from Western blotting showed that NM treatment dose-dependently decreased the expression of thrombin from an ischemic striatum lesion (Fig. 3A). We also found that brain thrombin activity in the vehicle group at 24 hours after MCAO was significantly higher than that in the sham group; however, NM treatment (0.1 mg/kg and 1 mg/kg) significantly reduced brain thrombin activity at 24 hours after MCAO (Fig. 3B and C). These results show that NM treatment can decrease thrombin expression and activity in the brains of rats after MCAO.

Evidence shows that thrombin can enter into the brain parenchyma through an opened BBB after cerebral ischemia. At the same time, prothrombin is synthesized and significantly increased in the cerebral parenchyma during ischemia, which can be cleaved by Factor Xa to active thrombin in the brain. NM treatment (0.1 mg/kg and 1 mg/kg) significantly alleviated the progression of vascular disruption in the ipsilateral hemisphere striatum and reduced thrombin expression as measured by double staining with FITC-dextran (Fig. 4A–C), which was particularly decreased in the neurons of the ischemia striatum lesion (Fig. 4D and E).

**NM protected from neuronal death through thrombin inhibition in rats after MCAO.** Ischemic cell death was detected with TUNEL staining. TUNEL-stained positive cells were significantly increased at 24 hours after the tMCAO; however, NM (0.1 mg/kg, 1 mg/kg) treatment significantly reduced the numbers of TUNEL-stained positive cells and significantly ameliorated thrombin expression (Fig. 5A and B). Furthermore, the number of TUNEL-positive cells colocalized with thrombin was significantly decreased with NM (0.1 mg/kg, 1 mg/kg) treatment (Fig. 5C). These results indicate that NM has a neuroprotective effect via the inhibition of brain thrombin.

**NM treatment improved the neurological function in MCAO rats.** To further demonstrate the translational value of the NM neuroprotective effects in stroke, we assessed the NM effect on neurological function in rats after ischemia by behavioral tests. We found no differences in the behavior among all of the groups of animals before ischemia. The data from the cylinder test showed that there was no significant difference in the unilateral motor function between the NM-treated group and the MCAO group on day 7 after MCAO (Fig. 6A). Moreover, no significant difference was found in the spontaneous motor behavior of each group on day 7 or day 14 after MCAO as determined by the Open field test (Fig. 6B–E).

However, the Morris Water Maze test showed that NM-treated rats exhibited enhanced learning ability with more latencies compared with the MCAO group (Fig. 6F–I). No significant differences in velocity were found among all of the groups (Fig. 6I). In the following probe test, the NM group spent significantly more time in the platform quadrant (Fig. 6K), indicating that NM treatment can improve the ability of performance tasks associated with long-term memory in ischemic rats.

**Discussion**

In this study, we evaluated the effects of NM treatment in a rat model of transient focal cerebral ischemia for the first time and found that NM treatment during ischemia improved neurological outcomes and reduced brain infarct volume and brain edema.

The molecular mechanism of the neuroprotective effects of NM in the brain tissue of rats after MCAO was investigated. Our data showed that NM treatment suppressed the elevation of thrombin either from BBB leakage or from neurons themselves in the brain parenchyma. NM treatment also alleviated brain damage through the inhibition of thrombin activity, which resulted in protection from neuronal injury, as indicated by a decrease in TUNEL-stained positive cells in the brain. Furthermore, our results indicate that there may be a relationship between thrombin toxicity and the long-term cognitive deficits after stroke. In this study, NM treatment improved cognitive function after acute cerebral ischemia, suggesting that NM has beneficial effects during ischemia, at least in part, through the inhibition of thrombin expression and activity.

Thrombin has been reported to modulate ischemic, hemorrhagic and traumatic brain injury. The ischemic brain is characterized by high levels of thrombin expressed in the brain parenchyma or infused from the bloodstream as a result of BBB disruption. First, NM treatment decreased thrombin leakage from the neurovasculature. Factor Xa can cleave prothrombin to active thrombin in the blood. However, Factor Xa, prothrombin and thrombin are serine proteases. NM, as a serine protease inhibitor, reduced MCAO-induced thrombin leakage, possibly by the inhibition of thrombin cleavage proteases, resulting in decreased thrombin originating from the blood after MCAO. In hippocampal slice cultures of an *in vitro* model of ischemia, another thrombin inhibitor, hirudin, has been shown to attenuate neuronal death in the CA1 region. Second, it has been reported that ischemia-induced brain injury can further enhance the expression of prothrombin and thrombin in the brain parenchyma, particularly in neurons. Our data showed that ischemia-induced cellular injury, represented as counts of TUNEL-stained positive cells, was increased with thrombin expression and decreased with NM treatment, suggesting that severe cellular damage is influenced by thrombin activation, and NM treatment can block this effect to show a neuroprotective effect *in vivo*.

Thrombin exerts several extravascular effects mediated by the activation of a family of protease-activated receptors (PARs). Until now, four PARs have been discovered, PAR-1, PAR-2, PAR-3 and PAR-4, among which PAR-1, PAR-3 and PAR-4 can be activated by thrombin, whereas PAR-2 is activated by trypsin. Both neurons and glial cells express the PAR-1 protein. Accumulating evidence demonstrates that thrombin and its receptors play important roles in neuroinflammatory and neurodegenerative processes in the central and peripheral nervous system. PAR-1 is upregulated after anoxia in hippocampal slice cultures *in vitro* and in acute cerebral ischemia *in vivo*. Thrombin can bind to the PAR-1 receptor to activate PAR-1 leading to neuronal injury. PAR-1 activation has been reported to show several neuroprotective effects, including neurite retraction and cell death in hippocampal cultures and motoneurons. PAR-1 knockout mice had less brain edema formation, neuronal death, and behavioral impairment after bilateral common carotid artery occlusion. Treatment with SCH79797, a PAR-1 antagonist, significantly reduced the average area of severe vascular disruption and TUNEL-stained positive cells after focal ischemia. It might be possible that the neuroprotective effects of NM during ischemia are mediated not only by the inhibition of thrombin.
Figure 2 | The expression of thrombin was increased in the ischemic regions of MCAO rats. (A–B) The immunoreactivity of thrombin in the cortex and striatum of ischemic brain tissue. Scale bar = 100 μm. Significant thrombin antigen was found in regions of the ipsilateral hemisphere striatum. (C) Double staining examining the colocalization of thrombin with FITC-dextran staining in the striatum and cortex. Scale bar = 50 μm. (D) Significant FITC-dextran leakage present in the ipsilateral hemisphere striatum. (E) Significant amounts of thrombin were expressed in areas with severe FITC-dextran leakage regions. (F) Double staining examining the colocalization of thrombin with MAP-2-positive neurons. Scale bar = 50 μm. Immunohistochemistry with an anti-thrombin antibody and a neuronal marker anti-MAP-2 antibody revealed thrombin expression mostly in ischemic neurons. The white arrow indicates the colocalization of thrombin staining with FITC-dextran or neurons. ***p < 0.001, n = 6–8.
Figure 3 | Nafamostat mesilate (NM) treatment decreased the thrombin expression and activity induced by ischemia. (A) NM dose-dependently reduced thrombin expression in the ischemic regions as determined by Western blotting. (B) NM significantly inhibited ischemia-induced thrombin activity in the ischemic striatum. (C) NM dose-dependently inhibited ischemia-induced thrombin activity at 45 min of fluorescence determinate progression. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$ vs. Vehicle (MCAO group); **$P < 0.01$, ***$P < 0.001$ vs. sham group, $n = 6–8$. 
expression and activity but also by the prevention of PAR-1 receptor activation. Additional experiments are needed to clarify whether the PAR-1-activated signaling pathway is involved in NM-mediated neuroprotection.

Thrombin expression in the brain has also been associated with deleterious effects on cognitive function. When treated with an intracerebroventricular infusion of thrombin, rats committed significantly more reference memory errors and had higher task...
completion latencies in the eight-arm radial maze. Our results showed that brain ischemia caused long-term spatial memory impairment in the Morris Water Maze test, whereas postsischemic NM treatment significantly attenuated this memory impairment, suggesting that NM may attenuate the long-term spatial memory impairment induced by ischemia through thrombin inhibition.

In conclusion, our results provide evidence that NM had a neuroprotective role during ischemia-induced brain injury via the
Figure 6 | Nafamostat mesilate (NM) treatment improved an ischemia-induced cognitive deficit. NM treatment had no beneficial effects on unilateral motor function at 1 week after ischemia evaluated by the cylinder test (A), or on spontaneous motor behavior at 1 and 2 weeks after ischemia evaluated by the Open field test (B–E). (F–K) The cognitive functions of the animals were assessed by the Morris Water Maze test. After ischemia (Vehicle group), the animals had a longer latency time (F, G) and a longer swim path distance (H, I) during the test. No significant difference in the velocity was found among all of the groups (J). In the following probe test, the NM-treated rats spent a significantly longer time in the platform zone (K), indicating that NM treatment improves the ability of a performance task associated with long-term memory in ischemic rats. *P < 0.05, **P < 0.01, ***P < 0.001 vs. Vehicle (MCAO group); *P < 0.05, **P < 0.001 vs. sham group, n = 8–10.
inhibition of thrombin expression and activity in the brain, particularly in neurons, which suggests that NM could be a potential drug for the treatment of ischemic stroke patients.

**Methods**

**Chemicals and reagents.** Nafamostat mesilate (C_{19}H_{17}N_{5}O_{2}.2CH_{4}O_{3}S, 6-amino-2-naphthyl p-guanidinobenzoate dimethanesulfonate), a serum protease inhibitor, was obtained from NANJING D&R PHARMACEUTICAL COMPANY (China). Argatroban (C_{23}H_{36}N_{6}O_{5}S.H2O, 1-[3-[(aminomethyl)amino]-1-oxo-2-[[1,2,3,4-tetrahydro-3-methyl-8-quinolinyl]sulfonyl]aminopentyl]-4-methyl-2-piperidinercarbonylic acid) was purchased from Enzo Life Sciences (BML-P114, USA). Fluorescein isothiocyanate (FITC) dextran was purchased from Sigma-Aldrich (USA), goat anti-thrombin antibody was purchased from Santa Cruz Biotechnology (USA), rabbit anti-MAP-2 antibody purchased from Sigma-Aldrich (USA), Alexa Fluor 594-conjugated rabbit anti-rabbit IgG antibody and Alexa Fluor 354 conjugated donkey anti-goat IgG antibody were purchased from Invitrogen (CA). RIPA buffer and MicroBCA kit were purchased from Beyotime (China). Protease inhibitor cocktail mixture, and then intracardially perfused with 250 ml of saline followed by 300 ml of 4% paraformaldehyde. Coronal cryostat sections (20 μm) were obtained from frozen brains by serial sectioning. Sections of the brain were separated by 10% SDS-PAGE and transferred onto the PVDF membranes which were then blocked with 5% non-fat milk, and then incubated with primary antibodies overnight at 4°C. The following primary antibodies were used: goat anti-thrombin antibody (1:100), rabbit anti-MAP-2 antibody (1:800). After 3 times with PBS, sections were incubated with secondary antibodies: Alexa Fluor 488-conjugated goat anti-rabbit IgG antibody (1:400), Alexa Fluor 594 conjugated donkey anti-goat IgG antibody (1:400). The nuclei were counterstained with Hoechst 33258 for 20 minutes at room temperature. The fluorescent imaging was visualized by using Olympus fluorescence microscope (Japan).

**Western blotting.** Brain samples from ischemic and nonischemic brain tissue were homogenized with RIPA buffer supplemented with a protease inhibitor cocktail. Protein concentrations were measured with MicroBCA kit. Protein samples (30 μg) were separated by 10% SDS-PAGE and transferred onto the PVDF membranes which were immunoblotted with a polyclonal goat anti-thrombin antibody (1:1000). β-actin monoclonal antibody (1:10000) was used for detecting β-actin served as a loading control.

**Thrombin activity determination.** Thrombin activity was measured by use of a fluorometric assay as described previously with minor modifications. Briefly, animals were reanesthetized and perfused with saline. Brains were removed and cut into 6–8 mm thick sections (1 mm thickness) using a mouse brain slicer micer. After weighing, each brain section was transferred to a well in a 96-well black microplate which was prefilled with 50 μl assay buffer (50 mM Tris-HCl, pH=8, 150 mM NaCl, 1 mM CaCl_{2}, 0.1% BSA, Benzoin-Phe-Val-Arg-AMC-HCl (13 μM), protease inhibitor prolyl endopeptidase inhibitor II (20 μM)) in each well. After 100 μl assay buffer was added to each well before measurement. The kinetic fluorescence was determined for 45 minutes at 25°C using a fluorescence detection system (Magellan V6.6; Safire2, Tecan; excitation 360–380 nm, emission 440–460 nm).

**Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining.** At 24 h after MCAO, mice were deeply anesthetized with pentobarbital sodium and perfused with 4% paraformaldehyde. Coronal cryostat sections (20 μm) were obtained from frozen brains by serial sectioning. Sections of the striatum through the striatum were chosen for TUNEL staining. The TUNEL staining was performed according to the manufacturer’s instructions (Roche Molecular Biochemicals, Swiss). The brain sections were counterstained with Hoechst 33342 to visualize nuclei. We detected TUNEL-positive cells in the striatum of ischemic brain tissue were counted in random areas, and the number of TUNEL-positive cells was counted at 20× magnification photograph.

**Behavioral tests.** Behavioral tests were conducted to assess the motor function as well as memory and learning ability of the ischemic rats. Ischemic rats were randomly assigned to receive drug treatments during ischemia: Nafamostat mesilate (0.01, 0.1 and 1 mg/kg), argatroban (3.4 mg/kg). One week after ischemia onset, these animals were tested using the cylinder test. Briefly, the animals were placed in a 20 cm wide transparent glass cylinder and a video camera was used to record a minimum of 20 contacts of each forepaw with the wall of the glass cylinder. Data was recorded as left, right and total. The average number of contacts was divided by the total distance traveled. Each trial was repeated five times per day for 1 week. During the tests, rats were kept away from the testing environment and the activity was recorded immediately after the mice were placed in the open field apparatus.

**Spatial learning/memory was tested using a Morris water maze as described previously.** Briefly, Morris water maze task was carried out between days 21 and 30 after tMCAO. A platform to escape from the circular pool was hidden under the water surface. Rats received one trial per day for 6 days. For each trial, rats were facing the pool side placed into a small pool of water and were allowed to swim in water for 60 s (it took up to 6 days to train the rats). When the rats swam around the pool to find the platform, various parameters such as the time taken to reach the platform (latency), velocity and swimming paths were recorded by a video imaging analysis system (EthoVision®3, Noldus Information Technology). Rats that failed to locate the platform at the end of 60 s were helped to find the platform for 30 s. At day 7, a probe test was performed to measure the retention of spatial memory when the platform was removed. The time spent in the target quadrant was recorded.

**Statistical analysis.** Statistical analysis was carried out with GraphPad Prism 5 software (San Diego, CA). Values were tested using the student’s t-test or ANOVA as appropriate. All data were expressed as mean ± SEM. Multivariate analysis of variance (MANOVA) was conducted by statistical software StatView (SAS) in Morris Water Maze test. P < 0.05 was defined to indicate a statistically significant difference.
7. Schoenmakers, S. H., Reitsma, P. H. & Spek, C. A. Blood coagulation factors as inflammatory mediators. Blood Cell Mol. Dis. 34, 30–37 (2005).
8. Xi, G., Reiser, G. & Keep, R. F. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J. Neurochem. 84, 3–9 (2003).
9. Chen, B. et al. Thrombin activity associated with neuronal damage during acute focal ischemia. J. Neurosci. 32, 7622–7631 (2012).
10. Hua, Y., Wu, J., Keep, R., Hoff, J. & Xi, G. in Brain Edema XII 163–166 (Springer, 2003).
11. Shikamoto, Y. & Morita, T. Expression of factor X in both the rat brain and cells of the central nervous system. FEBS Lett. 463, 387–389 (1999).
12. de Castro Ribeiro, M. et al. Thrombin in ischemic neuronal death. Exp. Neurol. 198, 199–203 (2006).
13. Okajima, K., Uchiba, M. & Murakami, K. Nafamostat mesilate. Cardiovasc. Drug Rev. 13, 65–69 (1995).
14. Hitomi, Y., Ikari, N. & Fujii, S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Pathophysiol. Haemo. Thromb. 15, 164–168 (1985).
15. Uchiba, M., Okajima, K., Abe, H., Okabe, H. & Takatsuki, K. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb. Res. 74, 155–161 (1994).
16. Vivien, D. & Buisson, A. Serine protease inhibitors: novel therapeutic targets for stroke? J. Cereb. Blood Flow Metab. 20, 755–764 (2000).
17. Wang, J., Jin, H., Hua, Y., Keep, R. F. & Xi, G. Role of protease-activated receptor-1 in brain injury after experimental global cerebral ischemia. Stroke 43, 2476–2482 (2012).
18. Cuomo, O. et al. Antithrombin reduces ischemic volume, ameliorates neurologic deficits, and prolongs animal survival in both transient and permanent focal ischemia. Stroke 38, 3272–3279 (2007).
19. Dihanich, M., Kaser, M., Reinhard, E., Cunningham, D. & Monard, D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 6, 575–581 (1991).
20. Riek-Burchardt, M., Strigov, F., Henrich-Noack, P., Reiser, G. & Reymann, K. Increase of prothrombin-mRNA after global cerebral ischemia in rats, with constant expression of protease nexin-1 and protease-activated receptors. Neurosci. Lett. 329, 181–184 (2002).
21. Sanchez, A. et al. Neurovascular unit and the effects of dosage in VEGF toxicity: role for oxidative stress and thrombin. J. Alzheimers Dis. 34, 281–291 (2013).
22. Hua, Y., Keep, R. F., Gu, Y. & Xi, G. Thrombin and brain recovery after intracerebral hemorrhage. Stroke 40, 588–89 (2009).
23. Tripathy, D. et al. Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front. Aging Neurosci. 5, 19 (2013).
24. Macfarlane, S. R., Seatter, M. J., Kanke, T., Hunter, G. D. & Plevin, R. Proteinase-activated receptors. Pharmacol. Rev. 53, 245–282 (2001).
25. Coughlin, S. R. Thrombin signalling and protease-activated receptors. Nature 407, 258–264 (2000).
26. Sokolova, E. & Reiser, G. Prothrombin/ thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: Localization, expression and participation in neurodegenerative diseases. Thromb. Haemostasis. 100, 576–581 (2008).
27. Wang, H. & Reiser, G. Thrombin signaling in the brain: the role of protease-activated receptors. Biol. Chem. 384, 193–202 (2003).
28. Rohatgi, T., Sedezhade, F., Reymann, K. G. & Reiser, G. Protease-activated receptors in neuronal development, neurodegeneration, and neuroprotection: thrombin as signaling molecule in the brain. Neuroscientist 10, 501–512 (2004).
29. Luo, W., Wang, Y. & Reiser, G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res. Rev. 56, 331–345 (2007).
30. Junge, C. E. et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc. Natl. Acad. Sci. U.S.A. 100, 13019–13024 (2003).
31. Turgeon, V. L., Lloyd, E. D., Wang, S., Festoff, B. W. & Houenou, L. J. Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. J. Neurosci. 18, 6882–6891 (1998).
32. Donovan, F. M., Pike, C. J., Gotman, C. W. & Cunningham, D. D. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J. Neurosci. 17, 5316–5326 (1997).
33. Turgeon, V. L., Milligan, C. E. & Houenou, L. J. Activation of the protease-activated thrombin receptor (PAR)-1 induces motoneuron degeneration in the developing avian embryo. J. Neurophysiol. Exp. Neurol. 58, 499–504 (1999).
34. Almonte, A. G. & Sweett, J. D. Serine protease, serine protease inhibitors, and protease-activated receptors: roles in synaptic function and behavior. Brain Res. 1407, 107–122 (2011).
35. Mhatre, M. et al. Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol. Aging 25, 783–793 (2004).
36. Longa, E. Z., Weinstein, P. R., Carlson, S. & Cummins, R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84–91 (1989).
37. Kawai, H., Yuki, S., Sugimoto, J. & Tanaka, Y. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 278, 780–783 (1996).
38. Lyden, P. et al. Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models. Stroke 45, 896–899 (2014).
39. Kilic, E., Ozdemir, Y. G., Hayrunnisa Bolay, H. K. & scedil. Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. J. Cereb. Blood Flow Metab. 19, 511–516 (1999).
40. Tsubokawa, T. et al. Cathepsin and calpain inhibitor E64d attenuates matrix metalloproteinase-9 activity after focal cerebral ischemia in rats. Stroke 37, 1888–1894 (2006).
41. Galvão, R. P., Garcia-Verdugo, J. M. & Alvarez-Buylla, A. Brain-derived neurotrrophic factor signaling does not stimulate subventricular zone neurogenesis in adult mice and rats. J. Neurosci. 28, 13368–13383 (2008).
42. Bushi, D. et al. Quantitative detection of thrombin activity in an ischemic stroke model. J. Mol. Neurosci. 51, 844–850 (2013).
43. Mu, J., Ostrowski, R. P., Krafft, P. R., Tang, J. & Zhang, J. H. Serum leptin levels decrease after permanent MCAo in the rat and remain unaffected by delayed hyperbaric oxygen therapy. Med. Gas Res. 3, 8 (2013).
44. Chan, C. B. et al. Phosphoinositide 3-kinase enhancer regulates neuronal dendritogenesis and survival in neocortex. J. Neurosci. 31, 8083–8092 (2011).